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Activation of the transcription factor Nrf2 (nuclear factor-erythroid 2-related factor 2) is one of the major
cellular defense lines against oxidative and xenobiotic stress, but also inﬂuences genes involved in lipid
and glucose metabolism. It is unresolved whether the cytoprotective and metabolic responses mediated
by Nrf2 are connected or separable events in non-malignant cells. In this study we show that activation
of Nrf2, either by the small molecule sulforaphane or knockout of the Nrf2 inhibitor Keap1, leads to
increased cellular glucose uptake and increased glucose addiction in ﬁbroblasts. Upon Nrf2 activation
glucose is preferentially metabolized through the pentose phosphate pathway with increased production
of NADPH. Interference with the supply of glucose or the pentose phosphate pathway and NADPH
generation not only hampers Nrf2-mediated detoxiﬁcation of reactive oxygen species on the enzyme
level but also Nrf2-initiated expression of antioxidant defense proteins, such as glutathione reductase and
heme-oxygenase1. We conclude that the Nrf2-dependent protection against oxidative stress relies on an
intact pentose phosphate pathway and that there is crosstalk between metabolism and detoxiﬁcation already
at the level of gene expression in mammalian cells.
& 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Cells are constantly challenged by xenobiotic and oxidative insults.
Nrf2 (nuclear factor-erythroid 2-related factor 2), a ubiquitously
expressed transcription factor of the cap 'n' collar basic leucine zipper
family, is a major part of the cellular defense against those harmful
stressors. Like most transcription factors, Nrf2 underlies a spatio–
temporal regulation of its function. Under unstressed conditions, the
level of Nrf2 protein is kept at low levels by binding to its most
prominent inhibitor Kelch-like ECH-associated protein (Keap) 1 in a
1:2 M ratio. Keap1, being an adapter for Cul3/Rbx1 E3 ubiquitinB.V.
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Open access under CC BY-NC-NDligases, facilitates constant proteasome-dependent degradation of
Nrf2. Upon exposure to oxidative or electrophilic agents, Keap1 acts
as redox or xenobiotic sensor via oxidation or covalent modiﬁcation
of some of its cysteine residues. This disrupts the Nrf2/Keap1
complex, stops degradation and favors stabilization of Nrf2 and
subsequent translocation to the nucleus. There, Nrf2 heterodimerizes
with Maf (small masculoaponeurotic ﬁbrosarcoma) proteins and
binds to ARE (antioxidant response element) consensus sequences
(TCAG/CXXXGC) in promoters of Nrf2-regulated genes. Those coun-
teract the initiating insults and are usually involved in drug metabo-
lism, the oxidative stress response and detoxiﬁcation [1–3].The
discovery of Nrf2 as main factor in the expression of cell defense
genes favored research exploiting Nrf2 as target of drugs or nutri-
tional supplements. Several plant- and food derived products are
capable of activating Nrf2, including Michael reaction acceptors (such
as curcumine from turmeric), isothiocyanates (such as sulforaphane
from cruciferous vegetable), polyenes (such as chlorophyll or por-
phyrins) or oxidizable (di)phenols (such as resveratrol from grapes)
[4]. They beneﬁcially inﬂuence the outcome in many models of
disease, including cancer, vascular disease, type II diabetes or
neurodegenerative disorders. These conditions are characterized or
caused, at least to some extent, by a tilt of the redox balance towards
oxidative stress which is thought to be alleviated or prevented upon
Nrf2 activation. However, they are also linked with altered metabo-
lism. Of note, beyond mere antioxidant and detoxiﬁcation duties of
Nrf2, gene arrays revealed that activated Nrf2 regulates clusters of license.
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both positive and negative inﬂuence on lipogenesis, depending on
the model system used [6–8], and certain cancer cells exploit
constitutive activation of Nrf2 to reprogram their metabolism for
securing optimal supply with biosynthetic building blocks [9]. How-
ever, whether the cellular antioxidant defense and the metabolic shift
elicited by Nrf2 are interconnected in non-malignant cells has not
been elucidated in detail.
We therefore investigated a potential interplay between Nrf2-
mediated cytoprotection and cellular glucose metabolism in
mouse embryonic ﬁbroblasts (MEFs) as model system. In order
to rule out metabolic adaptations to distinct proliferation rates
upon different treatments, we used quiescent (growth factor
depleted) cells throughout the study. We obtained transient
pharmacological activation of Nrf2 by treatment with the Nrf2
activator sulforaphane (SFN) [10]. Nrf2-dependent activity of SFN
was conﬁrmed by a lacking response in isogenic Nrf2−/− cells.
Genetic knockout of the Nrf2 inhibitor Keap1 served as model for
constitutive Nrf2 activation.Materials and methods
Materials
Mouse embryonic ﬁbroblasts (WT, Nrf2−/− and Keap1−/−) were a
kind gift from Thomas Kensler, University of Pittsburgh, USA. SFN,
menadione and other chemicals or enzymes were obtained from
Sigma-Aldrich, unless stated otherwise. Accutase for serum-free cell
detachment was from Millipore. Tritium-labeled 2-desoxyglucose
was provided by Amersham. Amplex Red and H2DCF-DA were from
Invitrogen. The CellTiterGlo assay for determination of cellular ATP
levels came from Promega. The kit for NADPH determination was
purchased from BioVision, and the exogenous enzymatic NADPH
generation system was from BD Biosciences and was used in a 1:20
dilution of solution A (NADP+ and glucose-6-phosphate; cat. no.
451220) and a 1:100 dilution of solution B (glucose-6-phosphate
dehydrogenase (G6PD); cat. no. 451200). The primary antibody
directed against heme oxygenase (HO-1) was from Stressgen, the
one against glutathione reductase (GR) was from Santa Cruz, the
secondary horseradish peroxidase (HRP) coupled anti-rabbit anti-
body was obtained from Cell Signalling, and the secondary anti-
mouse antibody was purchased from mpbio.
Cell cultivation and treatment
Mouse embryonic ﬁbroblasts (MEFs) were routinely subculti-
vated in Dulbecco's modiﬁed essential medium (DMEM containing
5 g/L glucose) supplemented with 10% heat inactivated fetal calf
serum and 2 mM glutamine and used up to passage 6. Except for
traces of insulin from the added serum, no extra insulin was
present during cultivation and experiments. For all experiments,
cells were seeded in appropriate plates and grown to approxi-
mately 80–90% conﬂuency and then rendered quiescent by deple-
tion of serum (0.1% serum) for at least 18 h. For withdrawal of
glucose, old medium was aspirated, cells were washed twice with
phosphate-buffered saline (PBS) and then glucose free DMEM
(Invitrogen) was added to cells for at least 24 h prior to assessment
of the readout of interest. For pharmacological activation of Nrf2,
cells were treated with 5 mM SFN for 3–7 h.
Determination of the cellular glucose uptake rate
MEFS were seeded into 12-well plates. After treatment as
indicated cells were equilibrated in standard Krebs Ringer Phos-
phate HEPES (KRPH) buffer containing 0.2% bovine serum albumin(BSA) for 20 min. The glucose uptake was initiated by addition of
2-deoxy-D-glucose spiked with 2-deoxy-D-(1H3)-glucose (ﬁnal
concentrations 0.1 mM and 0.45 mCi/mL). After 15 min the reaction
was stopped by three rapid washes with ice-cold PBS. The glucose
uptake rate was determined by liquid scintillation counting
(Perkin Elmer, Waltham, MA, USA) of cell lysates (lysis by 0.05 N
NaOH in PBS) and normalized to protein content assessed by the
Bradford protein assay and uptake time (to obtain incorporated
moles of glucose per milligram of protein per minute).Determination of the extracellular lactate as marker for glycolysis
MEFs were seeded into 24-well plates. After treatment as
indicated cells were washed with PBS and then incubated with
KRPH buffer supplemented with 0.2% BSA and 10 mM glucose for
2 h. Then supernatants were analyzed for their lactate content via
an enzyme-coupled and ﬂuorescent assay, and cells were lysed
and their protein content was determined. Brieﬂy, one volume
supernatant (usually diluted 1:20) was mixed with one volume
assay buffer (KRPH buffer with 10 mM Amplex Red, 1 U/mL lactate
oxidase and 2.5 U/mL horseradish peroxidase), incubated for
10 min and then read in a ﬂourimeter at an excitation wavelength
of 535 nm and emission wavelength of 590 nm. Parallel monitor-
ing of solutions with known concentrations of lactate facilitated a
ﬁnal readout of moles of lactate per gram of protein per minute.Determination of cellular ATP levels
MEFs were prepared in 12-well plates. After treatment as
indicated cells were detached, and an aliquot of the cell suspen-
sion was counted in a Vicell cell viability analyzer (Beckman) to
obtain the number of cells per milliliter. Another aliquot was
analyzed in a ATP sensitive luminescence kit (Cell Titer Glo,
Promega) according the manufacturer's instructions. ATP was
quantiﬁed by parallel assessment of a standard curve with known
concentrations of ATP. This allowed moles of ATP per cell as the
ﬁnal readout. ATP derived from glycolysis was determined by
blocking mitochondrial ATP production by 6 mM oligomycin (OM),
and ATP originating from OXPHOS was monitored in the presence
of the glycolytic inhibitor 20 mM deoxyglucose (DOG) or 200 mM
3-bromopyruvate (3BP). The portion of glycolytic ATP was then
determined as (ATP in the presence of OM/total ATP levels)100,
whereas the portion from OXPHOS was deﬁned as (ATP in the
presence of DOG or 3BP/total ATP levels)100.Determination of the NADPH/NADP ratio
MEFs were prepared in 12-well plates. After treatment as
indicated, cells were subjected to an assessment of the cellular
NADPH/NADP ratio with a kit from BioVision according to the
manufacturer´s instructions.Determination of the cellular level of reactive oxygen species (ROS)
MEFs were prepared in 12-well plates. After the indicated
treatment, 10 mM H2DCF-DA (Invitrogen) were added to the cells.
After 20 min, cells were detached by accutase treatment and
analyzed in a ﬂow cytometer (FACS Calibur, BD) recording the
green ﬂuorescence of oxidized DCF. The mean ﬂuorescence of
10,000 analyzed cells (corrected for auto-ﬂuorescence) was taken
as readout for the intracellular ROS load. Exogenous redox stress
was induced by addition of 25 mM menadione.
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Pharmacological inhibition of G6PD was obtained by incuba-
tion of cells with 100 mM dehydroandrostendione (DHEA). siRNA-
mediated knockdown of the enzyme was obtained as follows. Cells
were seeded in 6-well plates and transfected with siRNA using
oligfectamine according to the manufacturers' instructions. siRNA
directed against murine G6PD was from Ambion (silencerSelect)
and applied in a ﬁnal concentration of 100 nM, scrambled control
siRNA was from Invitrogen. Knockdown was maximal between 24
and 48 h (as determined by western blot analysis) and ranged
between 70% and 80% efﬁciency.Real-time quantitative polymerase chain reaction (RTq-PCR)
RNA isolation and subsequent cDNA synthesis were performed
according to the instructions of the manufacturer, using the
PeqGOLD Total RNA kit (Peqlab) and Superscript™ First-Strand
Synthesis System (Invitrogen), respectively. The real-time quanti-
tative PCR (RTq-PCR) was carried out using Light Cycler™ LC480
SYBR Green I Master reagent (Roche Diagnostics) in a reaction
volume of 15 mL. QuantiTects Primer Assays for murine heme
oxygenase 1 (target) and murine hypoxanthin-phosphoribosyl-
transferase (reference) were obtained from Qiagen, diluted and
aliquoted as recommended by the manufacturer. PCR contained
one denaturation step (10 min at 95 1C) and up to 40 ampliﬁcation
cycles (annealing step: 30 s at 61 1C and elongation step: 15 s at
72 1C). Melting curves of the ampliﬁed DNA were analyzed to
make sure that the PCR resulted in ampliﬁcation of one speciﬁc
product only. Data were analyzed using the Light Cycler™ LC480
Software (Roche Diagnostics) and the 2–ΔΔCt method.Protein extraction, SDS-polyacrylamide electrophoresis and
immunoblot analysis
MEFs were prepared in six-well plates. After the indicated
treatments, cells were washed with ice-cold PBS and scraped into
100 mL standard RIPA buffer. After a short pulse of sonication,
lysates were centrifuged to pellet insoluble debris. Supernatants
were subjected to protein determination according to Bradford.
Per lane of a gel, 10–20 mg protein were heat-denatured in 1 SDS
sample buffer and then electrophoretically separated on 10% SDS
polyacrylamide gels. After electrophoresis, proteins were trans-
ferred to an Immobilon (BioRad) membrane. Free binding sites of
the membrane were blocked with 5% dry milk powder in Tris-
buffered saline with Tween (TBS–T) before the membranes were
probed with the antibodies of interest. Visualization of the
antigen-antibody complex was achieved by enhanced chemolu-
minescence and recorded in Fuji LAS 3000 CCD camera. Densito-
metric analysis was performed using the AIDA software (Fuji).Statistics
All experiments were performed at least three times. Unless
stated otherwise, the bar graphs depict mean+SEM (standard error
of the mean). Two groups were compared using Student´s t test,
more groups were analyzed by one- or two-way ANOVA depend-
ing on the number of variables in the investigated data sets,
followed by Dunnett's or Bonferroni's post test. All statistical
analyses were done with GraphPad Prism. Differences with
p-valueso0.05 were considered as signiﬁcant and are designated
with * in the ﬁgures.Results
In order to get a ﬁrst insight into a potential interdependence
between Nrf2-mediated cytoprotection and glucose metabolism,
we assessed the cellular glucose uptake rate upon activation of
Nrf2. Knockout of Keap1 or pharmacological Nrf2 activation by
SFN increased the cellular glucose uptake rate approximately two-
fold and 1.5-fold, respectively, compared to the respective control
cells (Fig. 1A). Nrf2 knockout cells failed to exhibit an increased
cellular glucose uptake rate upon treatment with SFN, demon-
strating Nrf2-dependency and excluding an unspeciﬁc effect of the
small molecule (Fig. 1B). Moreover, cells with activated Nrf2, be it
by knockout of Keap1 or treatment with SFN, were less capable of
coping with glucose withdrawal over time and showed signiﬁ-
cantly decreased viability compared to control cells with basal
Nrf2 activity (Fig. 1C). A control experiment performed in parallel
in the presence of glucose revealed unaltered cell viability over
time excluding a time-dependent negative impact of SFN or Keap1
knockout on cell viability (data not shown).
Next, we aimed for deciphering the metabolic route of the plus
of ingested glucose. We determined the rate of aerobic glycolysis
upon activation of Nrf2. The excreted lactate levels, a surrogate
marker of glycolysis, were comparable between control cells, cells
with genetically or pharmacologically activated Nrf2 and cells with
depleted Nrf2 (Fig. 2A). Cellular ATP levels remained unchanged
demonstrating that glucose is not diverted for energy production
upon activation of Nrf2 (Fig. 2B). Moreover, the portions of ATP
derived from oxidative phosphorylation and glycolysis determined
in the presence of DOG or 3BP and oligomycin, respectively,
(see also Materials and methods) were not signiﬁcantly different
between control cells and cells with activated Nrf2 (data not
shown). We further examined the cellular ratio of NADPH/NADP,
as readout for the activity of the pentose phosphate pathway (PPP)
which routes glucose-6-phosphate into production of NADPH and
ribose-5-phosphate. Keap1−/− cells display signiﬁcantly higher
cellular NADPH levels than WT cells (Fig. 2C), in line with the
notion that several enzymes of the PPP are under the control of
Nrf2 [5]. Inhibition of the key enzyme of the PPP, glucose-6-
phosphate dehydrogenase (G6PD), by dehydroandrostendione
(DHEA) [11] abolished the increase of NADPH, showing that
G6PD and the PPP are the main sources of the observed elevated
NADPH. Also WT cells treated with the Nrf2 activator SFN possess
a signiﬁcantly higher NADPH/NADP ratio than vehicle-treated
cells, whereas Nrf2−/− cells fail to respond to SFN treatment and
hereby conﬁrm the Nrf2-dependent action of SFN (Fig. 2D).
NADPH is a pivotal source of reducing equivalents and required
for enzymatic regeneration of the reduced forms of the cellular
redox buffers thioredoxin and glutathione, as well as cofactor
for several Nrf2-dependent detoxiﬁcation genes including NAD(P)
H:quinone oxidoreductase 1 (NQO1). We therefore checked the
reliance of the Nrf2-controlled ROS detoxiﬁcation on glucose
availability and a functional PPP. Cells are signiﬁcantly less capable
of detoxifying imposed redox stress upon activation of Nrf2 by SFN
when glucose is depleted or G6PD is inhibited either by DHEA or
by siRNA-mediated knockdown (average obtained knockdown
70–80%). Detoxiﬁcation of menadione-induced ROS by SFN is Nrf2-
dependent since it is blunted in Nrf2−/− cells (Fig. 3A). Moreover,
Keap1−/− cells cannot detoxify menadione-induced redox stress to the
same extent upon glucose depletion or inhibition of G6PD as in the
presence of glucose and an intact PPP (Fig. 3B). Interestingly, the
impact of glucose depletion or of interference with G6PD activity
becomes evident not only at the functional detoxiﬁcation of ROS, but
already on the level of Nrf2 target gene expression. Withdrawal of
glucose or inhibition of G6PD activity by DHEA abrogates the
induction of the selected antioxidant Nrf2-target genes glutathione
reductase (GR) or heme oxygenase-1 (HO-1) by SFN (Fig. 3C).
Fig. 1. Activation of Nrf2 results in increased cellular glucose uptake and glucose addition. (A) In quiescent mouse embryonic ﬁbroblasts Nrf2 was activated (black bars)
either by knockout of Keap1 (Keap1−/−) or treatment with sulforaphane (SFN, 5 mM) for 7 h. The cellular glucose uptake rate was determined as described in Materials and
methods. The graph compiles data of three independent experiments expressed as fold increases compared to wildtype (WT) cells with basal Nrf2 activity (* po0.05,
Student's t-test, mean+SEM). (B) Quiescent WT and Nrf2−/− MEFs were treated with vehicle (DMSO, D) or 5 mM SFN for 7 h before their glucose uptake rate was determined.
The graph compiles data of three independent experiments expressed as fold increases compared to vehicle-treated control cells (npo0.05, Student's t-test, mean+SEM).(C)
Control cells with basal Nrf2 activity and cells with activated Nrf2 (treatment with 5 mM SFN or Keap1−/− cells) were cultivated in absence of glucose as indicated. After the
given periods of time cell viability was assessed based on Trypan Blue exclusion and analyzed in an automated cell viability analyzer. The depicted graph compiles data from
three independent experiments. (* po0.05 (compared to WT cells at the respective time point, ANOVA, mean+SEM)).
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Nrf2-mediated gene transcription we further checked expression of
HO-1 in cells with depleted G6PD. Cells with reduced G6PD levels fail
to up-regulate HO-1 upon genetic and pharmacological activation of
Nrf2, both on the protein- (Fig. 3D) and mRNA- (Fig. 3E) levels. We
also conﬁrmed Nrf2-regulation of G6PD as seen by elevated G6PD
levels upon Nrf2 activation. Supplementation with an exogenous
enzymatic NADPH generating system rescues protein expression of
GR and HO-1 in cells that were treated with DHEA or depleted from
glucose (Fig. 4A). Exogenous NADPH also restored Nrf2-dependent
HO-1 expression on the mRNA level in cells that were deprived of
glucose or G6PD activity (Fig. 4B).
Based on these ﬁndings we conclude that Nrf2 activation
boosts cellular glucose uptake and metabolism through the PPP
to provide NADPH which is pivotal for Nrf2-mediated ROS detox-
iﬁcation on the functional and transcriptional level.Discussion
In this study we demonstrate the metabolic facet of the
cytoprotective transcription factor Nrf2. Our ﬁndings underline
the notion that activation of transcription factors or cellular
signaling events, which ultimately result in an altered gene
expression and a changed cellular phenotype (e.g. proliferation
and inﬂammation), is inseparably coupled with changes in cellular
metabolism and vice-versa [12]. This is not different upon activa-
tion of Nrf2. In order to cope with the cellular demand of an
increased antioxidant response, cells take up more glucose andshuttle it through the PPP for NADPH production, in line with the
notion of PPP enzymes being Nrf2 target genes themselves.
NADPH is crucial for maintaining an intact cellular buffer system
against redox stress by providing reducing equivalents to allow
glutathione or thioredoxin redox cycling. In addition, NADPH is a
cofactor of NQO1, a validated Nrf2 target gene and involved in
detoxiﬁcation of quinones. NQO1 may, thus, be involved in the
detoxiﬁcation of menadione-induced redox stress upon Nrf2
activation, as seen in Fig. 3. As we show here, interference with
the ﬂux of glucose through PPP hampered not only ROS detox-
iﬁcation on the functional level due to insufﬁcient NADPH avail-
ability but already on the level of Nrf2-triggered gene expression.
The expression of ROS detoxiﬁcation enzymes seems to be halted
if sufﬁcient supply with necessary co-factors is not guaranteed.
Such feedback regulation may spare the cell from futile de novo
protein expression. A link between the PPP and the transcriptional
antioxidant response upon an oxidative insult has already been
reported in yeast [13], and is very likely to be mediated by Nrf2 in
mammalian cells.
Our ﬁndings raise several issues which warrant further detailed
investigations at the interface of Nrf2-dependent cellular detoxiﬁ-
cation and glucose metabolism. In light of the observed increased
cellular glucose uptake rate obvious questions concern the connec-
tion between insulin signaling and Nrf2 on the one side, and level
and localization of glucose transporters after Nrf2 activation on the
other. Of note, insulin signaling is reported to activate Nrf2 [14] and
both insulin and Nrf2 activation trigger cellular glucose uptake. The
detailed causal connection and interdependency are not resolved
yet. It is tempting to speculate, though, that insulin, besides its
Fig. 2. Activation of Nrf2 does neither alter the cellular glycolytic rate nor ATP production, but enhances the cellular NADPH/NADP ratio. (A) The production of lactate by
MEFs with basal (white bars, DMSO(D) or WT), activated (black bars, SFN (5 mM, 7 h) or Keap1−/−) or lacking Nrf2 (gray bars) activity was determined as a readout for the
cellular glycolytic activity and normalized to the protein concentration derived from the cells. The bar graph depicts compiled data of three independent experiments.
(B) MEFs with basal (white bars, DMSO(D) or WT), activated (black bars, SFN (5 mM, 7 h) or Keap1−/−) or lacking Nrf2 (gray bars) activity were examined for their total ATP
levels normalized to cell count as described in Materials and methods (mM/cell). The bar graph depicts compiled data of three independent experiments. (C) The cellular
NADPH/NADP ratio was determined in cells with basal (white bars, WT and D(MSO), respectively) and activated Nrf2 (black bars, Keap1−/− and SFN (5 mM, 7 h), respectively)
as described in Materials and methods and referred to the value of untreated WT cells. Glucose-6-phosphate dehydrogenase was inhibited by 100 mM dehydroandros-
tendione (DHEA) and revealed the pentose phosphate pathway as main source of NADPH. Nrf2−/− MEFS conﬁrmed Nrf2-dependency of the increased NADPH/NADP upon SFN
treatment. (n¼3; * po0.05, ANOVA, Bonferroni, mean+SEM).
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tion of elevated glucose levels and by-products (such as redox
stress). A very recent study observed elevated Glut1 levels in brown
adipose tissue due to graded knockdown of Keap1 [15]. It will be
furthermore of interest to elucidate the molecular sensor of the
actual NADPH/NADP ratio that decides whether or not Nrf2-
dependent gene transcription occurs, and at what level Nrf2
signaling is interrupted. We have seen reduced Nrf2-dependent
protein and mRNA expression upon interference with the PPP.
However, it is still unresolved whether nuclear translocation or
stabilization of Nrf2 is also affected. We have selected HO-1 and GR
as representative Nrf2-target genes and observed that their expres-
sion is impaired upon withdrawal of glucose and disruption of the
PPP, respectively. It will be of interest to examine in a future
unbiased microarray analysis whether all Nrf2-dependent genes
are equally affected or if there are differences between different
promoters or functional clusters of Nrf2-dependent target genes.
Moreover, it will be of importance to analyze whether different
pharmacological activators show distinct dependency on glucose to
trigger Nrf2 activation. We have made our observations in non-
malignant mouse embryonic ﬁbroblasts. Future studies are war-
ranted to investigate the metabolic shade of Nrf2 in differentiated
specialized cell types. It will be e.g. of interest to see how Nrf2
activation affects the synthesis of fatty acids and cholesterol in
hepatocytes as these processes also need NADPH. Since fatty acidsynthase is negatively regulated by Nrf2 [16], it is conceivable that
Nrf2 activation directs NADPH mainly to the antioxidant machinery
and not towards reductive biosyntheses. Moreover, it will be
necessary to conﬁrm our in vitro observations made in cell culture
in appropriate in vivo/organ models in order to consider application
of Nrf2 activators/inhibitors in pathological settings. Chronically
high blood glucose levels, as found in patients with diabetes and
insulin resistance, are linked with increased redox stress, also due
to the ﬂux of glucose through the polyol and hexosamine pathway.
Future studies should clarify whether activation of Nrf2 in these
conditions could exert a double beneﬁcial action by (i) increasing
the cellular glucose uptake and diverting glucose to the PPP and (ii)
concomitantly boosting the cellular antioxidant response. Studies
demonstrating better glucose tolerance and insulin sensitivity after
Nrf2 activation in animal model of diabetes are in line with this idea
[15,17,18].
Overall, Nrf2 is a prominent player in protecting the cell against
oxidative and xenobiotic insults. In this study we revealed that
activation of Nrf2 goes along with increased cellular uptake and
metabolism of glucose through the PPP. The subsequent produc-
tion of NADPH is crucial for allowing not only functional detox-
iﬁcation of ROS but also Nrf2-controlled gene expression to occur.
This is the ﬁrst report to show that Nrf2-mediated detoxiﬁcation is
connected with a speciﬁc metabolic program in non-malignant
mammalian cells. Availability of glucose and a functional PPP are
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Fig. 3. Supply with glucose and a functional pentose phosphate pathway are necessary for the Nrf2-dependent detoxiﬁcation of ROS and expression of selected Nrf2 target
genes. (A) WT MEF, either kept in medium plus glucose or without glucose (−glc) or with impaired G6PD activity (DHEA, siG6PD) were treated with DMSO (D, white bars) or
5 mM SFN (7 h; black bars) and stressed with menadione (25 mM) as indicated. Nrf2−/− MEF served as control for Nrf2-dependent action of SFN. Then their intracellular ROS
levels were determined based on ﬂuorescence of oxidized DCF by ﬂow cytometry (large panel). The insert depicts the extent of SFN-mediated detoxiﬁcation of menadione-
induced redox stress ([1-(ΔROS(+menadione/−menadione)SFN/−(ΔROS (+menadione/−menadione)DMSO)]100) under each condition (n¼3; * po0.05, ANOVA, Dunnett,
mean+SEM). (B) Intracellular ROS levels in Keap1−/− MEFs were determined in the basal state and after imposure of exogenous oxidative stress by 25 mM menadione under
control conditions (ctrl), upon withdrawal of glucose (−glc), inhibition of G6PD by DHEA (100 mM) or knockdown of G6PD (siG6PD). The graph depicts the extent of
menadione-induced redox stress in each condition (i.e., ΔROS (+menadione/−menadione)) (n¼3; * po0.05, ANOVA, Bonferroni, mean+SEM). (C) WT MEFs were treated
with SFN (5 mM) in the presence of glucose or the G6PD inhibitor DHEA (100 mM) as indicated for 7 h before the expression level of the Nrf2 target genes glutathione
reductase (GR) and heme oxygenase (HO-1) as well as the loading control actin were determined by western blot analysis. Representative blots out of three independent
experiments are depicted. The numbers below the blot indicate the relative densitometric mean of all performed experiments (normalized to the respective loading control).
(D) MEFs were transfected with either scrambled (scr) siRNA or siRNA directed against G6PD as indicated. Activation of Nrf2 was then obtained either by Keap1 knockout
(genetic g) or treatment with SFN (5 mM) for 7 h (pharmacological p). Cell lysates were subjected to western blot analysis for HO-1, G6PD and actin. Representative blots out of
three independent experiments are depicted. The numbers below the blots indicate the relative densitometric mean of all performed experiments (normalized to the loading
control). (E) MEFs were transfected with either scrambled (scr) siRNA or siRNA directed against G6PD as indicated. Activation of Nrf2 was then obtained either by Keap1
knockout (g) or treatment with 5 mM SFN (p) for 3 h. mRNA levels of HO-1 were determined by RTqPCR analysis. (n¼3, * po0.05, ANOVA, Bonferroni, mean+SEM).
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